



AGENDA

Monday, July 27, 2020

10:00 a.m.	WELCOME <i>Dipti Itchhaporia, MD, FACC; ACC Vice President</i>
10:05 a.m.	Overview of Roundtable and Introductions <i>Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA and Michael D. Shapiro, DO, MCR, FACC, FAHA; Chair and Vice-Chair</i>
10:20 a.m.	SESSION 1: LDL-C: NEW AND EMERGING THERAPIES FOR THE HIGH-RISK PATIENT <ul style="list-style-type: none">• Non-Statin Therapies for LDL-Cholesterol Lowering: Ezetimibe and Bempedoic Acid <i>Anne Carol Goldberg, MD, FACP, FAHA, FNLA</i>• What is New for Inhibition of PCSK9? <i>Christie M. Ballantyne, MD, FACC, FACP, FNLA</i>• Interactive Breakout Session (45 minutes)• Report Back to Full Group (35 minutes)
12:10 p.m.	BREAK (10 minutes)
12:20 p.m.	SESSION 2: BARRIERS AND OPPORTUNITIES IN THE MANAGEMENT OF STATIN-ASSOCIATED SIDE EFFECTS (SASE) IN THE HIGH-RISK PATIENT <ul style="list-style-type: none">• Defining Statin Associated Adverse Events <i>Paul Thompson, MD, FACC</i>• Interactive Breakout Session (45 minutes)• Report Back to Full Group (35 minutes)
2:00 p.m.	Q&A AND RECAP SESSION (30 minutes)
	Address Questions from Webex Chat and Prioritize Next Steps <i>Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA and Michael D. Shapiro, DO, MCR, FACC, FAHA; Chair and Vice-Chair</i>
2:30 p.m.	ADJOURN